Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

OPTIMISMM trial investigators

Research output: Contribution to journalArticlepeer-review

171 Scopus citations

Fingerprint

Dive into the research topics of 'Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences